Bluejay Diagnostics Inc (BJDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bluejay Diagnostics Inc (BJDX) has a cash flow conversion efficiency ratio of -0.380x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.59 Million) by net assets ($4.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Bluejay Diagnostics Inc (BJDX) balance sheet quality index to measure how much of total assets are equity-financed.
Bluejay Diagnostics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Bluejay Diagnostics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Bluejay Diagnostics Inc (BJDX) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Bluejay Diagnostics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bluejay Diagnostics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Braemar Plc
LSE:BMS
|
0.012x |
|
NeutriSci International Inc
V:NU
|
0.006x |
|
Zephyr Energy PLC
LSE:ZPHR
|
0.043x |
|
Robert Walters
LSE:RWA
|
0.065x |
|
Migo Opportunities Trust PLC
LSE:MIGO
|
-0.009x |
|
Kovo Healthtech Corp
V:KOVO
|
0.032x |
|
Nicolas Miguet et Associes SA
PA:MLNMA
|
N/A |
|
EnSilica PLC
LSE:ENSI
|
0.203x |
Annual Cash Flow Conversion Efficiency for Bluejay Diagnostics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Bluejay Diagnostics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see BJDX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.98 Million | $-6.05 Million | -1.013x | +25.77% |
| 2024-12-31 | $5.73 Million | $-7.82 Million | -1.365x | +52.48% |
| 2023-12-31 | $2.89 Million | $-8.31 Million | -2.872x | -328.15% |
| 2022-12-31 | $11.54 Million | $-7.74 Million | -0.671x | -213.08% |
| 2021-12-31 | $20.38 Million | $-4.37 Million | -0.214x | -277.15% |
| 2020-12-31 | $-4.21 Million | $-508.71K | 0.121x | -79.02% |
| 2019-12-31 | $-2.93 Million | $-1.69 Million | 0.576x | -- |
About Bluejay Diagnostics Inc
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoas… Read more